Summary of survival and clinical outcomes
| . | Estimate (95% CI) . |
|---|---|
| 2-y OS | 74% (44-90) |
| 2-y PFS | 69% (39-86) |
| 2-y GRFS | 44% (20-66) |
| 2-y NRM | 16% (2.3-42) |
| 2-y relapse | 16% (3.7-36) |
| 6 m Gr II aGVHD | 16% (3.7-36) |
| 1-y cGVHD | 68% (41-85) |
| 1-y mod/severe cGVHD | 42% (20-63) |
| . | Estimate (95% CI) . |
|---|---|
| 2-y OS | 74% (44-90) |
| 2-y PFS | 69% (39-86) |
| 2-y GRFS | 44% (20-66) |
| 2-y NRM | 16% (2.3-42) |
| 2-y relapse | 16% (3.7-36) |
| 6 m Gr II aGVHD | 16% (3.7-36) |
| 1-y cGVHD | 68% (41-85) |
| 1-y mod/severe cGVHD | 42% (20-63) |
GRFS, severe aGVHD-free, moderate-severe cGVHD-free, and relapse-free survival. NRM, relapse, aGVHD and cGVHD are the cumulative incidence estimates.